ORIGINAL ARTICLE

Monitoring polymedicated elderly patients in a health care unit

C. Galán-Retamal,* R. Garrido-Fernández, S. Fernández-Espinola, and V. Padilla-Marín

Unidad de Gestión Clínica de Farmacia, Hospital Antequera, Área Sanitaria Norte, Málaga, Spain

Received July 13, 2009; accepted January 27, 2010

Abstract

Objective: To implement a coordinated strategy for the family care unit and the pharmacy division in order to enable revising treatment in polymedicated patients. To this end, we have developed a software tool permitting the patient’s primary doctor to have a quick, summarised description of the patient’s updated pharmacological treatments, and detect iatrogenic risks and/or dosage adjustments and pharmacotherapy advice.

Methods: In this study, polymedicated patients are defined as those taking 10 or more medications during at least one month.

Development phases:
Designing a guide form to assist the family doctor in reviewing treatments.
Developing a drug treatment report (DTR) as a complementary document to assist the doctor in reviewing treatments.
Introducing a coordinated communication system between the family doctor and the pharmacist.
Reviewing work instructions and distributing them to staff members involved.

Results: The target population of the study consists of 1897 polymedicated patients. We issued 1897 reports, containing the following: 8530 recommendations (10% alerts from regulatory authorities, 31% recommendations regarding high-risk drugs in elderly patients, 7% gave information about new treatments and 52% recommendations on proper drug use); 399 had high clinically relevant drug interactions; and 5036 dose adjustment recommendations. These pharmacotherapy reports allow treatment to be revised for nearly 100% of the selected population.

Conclusion: The development and implementation of software tools for monitoring polymedicated patients enables us to create DTRs that facilitate routine medical reviews of pharmacological treatment in a fairly wide range of patients.

© 2009 SEFH. Published by Elsevier España, S.L. All rights reserved.

KEYWORDS
Polymedicated;
Elderly;
Medication review;
Pharmacotherapy monitoring

*Declaration of preliminary publication: This project was sponsored by the Fundación Andaluza de Farmacia Hospitalaria (Andalusian Foundation for Hospital Pharmacy) and presented at the 5th Andalusian Hospital Pharmacy Society Congress held in Cordoba, Spain in April 2009.

*Corresponding author.
E-mail address: mariac.galan.sspa@juntadeandalucia.es (C. Galán-Retamal).
Introduction

The multitude of concomitant diseases in patients over 65 years of age produces a polypharmacy that is very difficult to manage and is susceptible to numerous medication errors and medication-related problems, causing hospital readmissions to increase. The risk of suffering an adverse reaction to medication is around 5%, a rate that rises to almost 100% when a patient takes 10 or more drugs. According to Plenary Agreement No. 714 of 25 March 2009, Act No. 85 of the Inter-Territorial Council of the National Health System, related to rational drug use, those individuals with chronic diseases who are taking more than 6 drugs on a continuous basis for 6 or more months are considered polymedicated.

In order to ensure quality care for polymedicated patients over 65 years of age, their treatment must be reviewed at least once a year, as recommended in the ACOVE project that establishes a set of minimum standards for quality care.

Doctors need to be able to quickly see a summary of their patients’ current drug treatment, iatrogenic risks, and/or dose adjustments and drug treatment recommendations. The development of a strategy to address this need came about in response to the ACOVE quality drug treatment criteria in elderly patients.

This publication describes the software tool and, more importantly, the design of a communication system between the family care unit and the pharmacy department that effectively adjusts drug treatments to the clinical conditions of polymedicated elderly patients.

Method

The project was developed in a health care area with a population of 106,756 inhabitants, of which 18% were over 65 years of age. The health care area had a total of 70 family doctors who provided care for four basic widely dispersed health districts.

The project was started in the last quarter of 2008 using the design from the reference documents: Review Form and Drug Treatment Report (DTR). In January 2009 the communication system between family doctors and the pharmacy department was started. Area family doctors are currently (May 2009) in the process of reviewing the treatment of their polymedicated patients, and we are reaching nearly 100% of the initial population.

In order to make the sample size of the target population acceptable, for this project we defined ‘polymedicated patient’ as any patient older than 65 years of age and who was taking 10 or more drugs over a period of a month or more.

The first phase of the project was to design a form for reviewing treatment. The objective of this document was to serve as a guide for family doctors for rationally reviewing drug treatment.
The Hamdy4 questionnaire was used as a reference for creating this form, and it includes patient characteristics, risk factors for adverse effects, appropriate medication use and type of intervention.

After the form was approved by the area’s pharmacy committee it was made available for download on the intranet.

We then proceeded to create a DTR (Figure) to serve as a support document for family doctors during the treatment review procedure.

This report was designed using the ACCESS version 2003 software application and included the following sections:

1. Patient identification data obtained through the MicroStrategy prescription billing programme, the corporate application used by the Servicio Andaluz de Salud (Andalusian Health Department, [SAS]) merged with the unique database of Andalusia, from which names, ages and doctor identification data were extracted.

2. Drug treatment: contains the medications collected by the pharmacy’s patient during the past month through the MicroStrategy SAS prescription database programme. Active ingredient, dosage, administration route and therapeutic group are given for medications.

3. Clinically relevant drug interactions. The Peral Aguirregoitia J et al5 publication served as the main source of information on the drugs involved, the degree of clinical relevance of drug interactions according to Hansten,6 Micromedex,7 Lexi-Comp8 and observations on the management of interactions.

4. Recommendations on dosage adjustment in kidney failure obtained from the Drug Therapy Guidelines of the Alicante General University Hospital Pharmacy Department,9 from the Spanish General Council of Pharmaceutical Colleges10 and from the David McAuley database.11

   5.1. Selection of potentially inappropriate drugs for the elderly. We used the Beers criteria12 as a reference and included three additional groups: insulin, oral anticoagulants and digitalic drugs as they cause adverse events that lead to a high incidence of emergency department visits.13

5.2. Quality indicators of appropriate use of medications. We used three sources of information: A. Recommendations for follow-up and monitoring of treatments with anticoagulants, diuretics, anticholinergics, oral anti-diabetic drugs, barbiturates, opioid analgesics and angiotensin enzyme converter inhibitors, and angiotensin receptor antagonists. B. Recommendations related to the medication selection objectives contained in the programme contract and the SAS clinical management agreement. These recommendations were developed by the expert group on rational medication use from the Pharmacy and Benefits Section.
C. Warning about the risk of anticholinergic effects with certain drugs using the Rudolph JL et al anticholinergic risk scale.14

5.3. Information on drugs classified by the Andalusian centre for drug information15 such as new treatments not recommended for use (NTNR) and new combinations not recommended for use (NCNR).

5.4. Information on warnings issued by regulatory agencies. These include those issued by the Spanish agency for medications and health products,16 the Food and Drug Administration (FDA)17 and the Drug Safety Update.18


7. Comments. Open text that includes observations on non-standardised treatment.

8. Pharmacist’s signature.

Lastly, the study instructions were edited and distributed among medical and pharmaceutical professionals with the backing of the hospital and primary care directors involved. In this way the communication system between family doctors and pharmacy departments was put into action.

The family doctor received a list from the pharmacy department with a list of all of their polymedicated patients and an personalised DTR for each patient.

The review form and the DTR are used as guidelines for treatment review.

The procedure was completed with the registration of the patient’s electronic medical history, creating a clinical health episode, including all interventions that result from the treatment review.

Results

The prevalence of polymedicated patients in our area amounts to 10% of the over 65s population; 19% take more than 8 drugs and 34% take more than 6.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Interactions</th>
<th>High risk medication</th>
<th>Regulatory agency warnings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylsalicylic acid+propionic acid derivatives</td>
<td>126</td>
<td>31.58</td>
<td></td>
</tr>
<tr>
<td>Macrolides+HMG CoA reductase inhibitors</td>
<td>88</td>
<td>22.06</td>
<td></td>
</tr>
<tr>
<td>HMG CoA reductase inhibitors+phenylalkylamines derivatives</td>
<td>44</td>
<td>11.03</td>
<td></td>
</tr>
<tr>
<td>HMG CoA reductase inhibitors+fibrates</td>
<td>22</td>
<td>5.51</td>
<td></td>
</tr>
<tr>
<td>Theophylline+fluoroquinolones</td>
<td>22</td>
<td>5.51</td>
<td></td>
</tr>
<tr>
<td>Acetylsalicylic acid</td>
<td>963</td>
<td>36.42</td>
<td></td>
</tr>
<tr>
<td>Lorazepam</td>
<td>244</td>
<td>9.23</td>
<td></td>
</tr>
<tr>
<td>Acenocoumarol</td>
<td>222</td>
<td>8.40</td>
<td></td>
</tr>
<tr>
<td>Zolpidem</td>
<td>198</td>
<td>7.49</td>
<td></td>
</tr>
<tr>
<td>Dipotassium clorazepate</td>
<td>190</td>
<td>7.19</td>
<td></td>
</tr>
<tr>
<td>Bioflavonoids</td>
<td>196</td>
<td>22.98</td>
<td></td>
</tr>
<tr>
<td>Amoxicillin/clavulanic acid</td>
<td>158</td>
<td>18.52</td>
<td></td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>152</td>
<td>17.82</td>
<td></td>
</tr>
<tr>
<td>Alpha-adrenergic blockers</td>
<td>137</td>
<td>16.06</td>
<td></td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>95</td>
<td>11.14</td>
<td></td>
</tr>
</tbody>
</table>

The target population ranges in age from 65 to 101 years, of which 30% are between 75 and 79 years and 60% are women.

We have reported data from the first 8 months after introducing the strategy (October 2008 to May 2009).

The pharmacy department issued 1897 DTR in which 399 had high clinically relevant drug interactions, 5036 dosage adjustment recommendations for kidney failure and 8530 drug therapy recommendations. Of the latter, 52% of recommendations were related to the appropriate use of medication, 31% provided information on high-risk medications, 10% covered regulatory agency alerts and 7% gave information about new drugs.

Table shows the main drug treatment or medications involved in the previous recommendations.

Discussion

Pharmaceutical intervention can adopt various pharmaceutical strategies for assessing drug treatment in polymedicated patients.19 One of the most effective strategies involves the pharmacist reviewing the patient’s treatment plan, filling out a DTR and then contacting the doctor in charge.20 Reports must be prepared quickly and communication streamlined with the family doctor, as it ensures that patient drug data and information reflected in the DTR, is as up-to-date as possible. This method is even more effective when the intervention is carried out on the current prescription and not retrospectively.21

There are few publications on this type of pharmaceutical intervention on large populations. Hanlon22 applied this intervention to 208 patients (DTR, recommendations for the doctor, interview and patient information programme). In similar studies, the number of patients does not differ much with respect to the previous sample and in all cases the therapeutic plan was reviewed by a pharmacist, interviews were conducted with the actual patients, DTR
were filled out and agreement reached with the doctors in charge.\textsuperscript{23,24}

In 2005, Zarowitz et al\textsuperscript{25} published their intervention with 6693 patients where pharmacists reviewed the therapeutic plan and presented a range of learning activities for both the patient and prescribing doctor, with truly surprising results in the initial phase of the study.

We would also like to point out an observational descriptive study carried out in our area using a telephone survey on 73 patients to detect possible errors in medication and to determine treatment adherence.\textsuperscript{26}

At the institutional level, we note the initiatives carried out by the Andalusian health service, whose clinical management contract with primary care for 2008 aims towards reviewing the medication of individuals older than 65 years who use 10 or more drugs. The role of the pharmacist in this case consists of obtaining lists of patients who meet these requirements and sending the lists to the various units. The family care units (medical and nursing staff) of these departments will then review the treatment.

A final example is the initiative carried out in the Community of Madrid, which even gives legal status to the review of treatments for polymedicated patients, as cited in Article 3 of Decree 6/2006 legislated in Madrid.\textsuperscript{27} Similar initiatives can be found in other communities.\textsuperscript{28}

We conclude that this type of strategy, where the pharmacist assessing polymedicated patients’ drug treatment plans, regardless of the level of care they are receiving, is crucial. As we have seen, if the assessment is followed by filling out a DTR, the intervention results even more effective. However, in most cases the pharmacy departments’ structure is incapable of supporting this workload. It is therefore essential that software tools be developed such as those proposed in this study in order to encompass the entire target population of the intervention.

In 2008, Yourman et al\textsuperscript{29} reviewed the impact of using electronic prescription systems on the quality of drug therapy plans in elderly patients. The aspect that interests us in this section is that the patient sample evaluated with this strategy increases significantly. Some authors focus their attention on the use of certain drug groups that are of particular risk for the elderly, such as hypnotics/sedatives, on samples sizes of more than 12 000 patients.\textsuperscript{30}

Along the same lines, electronic assistance has been designed for prescribing psychotropic medication in Brigham Hospital\textsuperscript{31} to reduce the risks of falls and avoid over-sedation and cognitive damage in elderly patients. The sample size was 3718 patients and 7456 medical prescriptions.

Another item worth noting is the controversy surrounding the transfer of lists of medications that are potentially inappropriate for use in elderly patients from one country to another. As such, within the Beers criteria almost half of the drugs are not marketed or in use within Europe. We must therefore supplement these criteria with literature sources that reflect our social context. We are not aware of any initiative at European level and which is therefore adapted to our environment. This point is central for the development of databases with explicit criteria, which would then allow us to make DTR automated.

The form designed for the doctor to review and assess treatment is based on the form proposed by Hamdy et al. It is simpler than others that are more complete but more difficult to fill out, such as the Medication Appropriateness Index (MAI).\textsuperscript{32}

In our literature review we did not find any publications that describe in detail the databases used (when used) or the scientific technical sources employed. Nor did we find a detailed description of a DTR obtained from the previously mentioned databases. This study aims to provide professionals with a software tool that allows them to contribute their knowledge to the multidisciplinary assessment of the polymedicated patient in those environments where there are no electronic prescription systems.

In the second phase we must determine the impact of pharmaceutical intervention on medical prescriptions and on the actual patient.

In conclusion, the review of the therapeutic plan for polymedicated patients constitutes an effective strategy since chronic diseases and complex treatments are the norm for this type of patient. Its effectiveness increases if the intervention is carried out on the entire target population. To this end, we must develop technical assistance methods for prescriptions in community care similar to those used in hospital care.

Conflict of interest

The authors affirm that they have no conflicts of interest.

References

28. BORM. Boletín Oficial de la Región de Murcia, 03 de Enero 2009 (núm. 2). Decreto número 585/2008 de 29 de diciembre, por el que se regula la concesión directa de una Subvención a la Fundación para la Formación e Investigación Sanitarias de la Región de Murcia, para la mejora de la Atención al Paciente con Enfermedades Crónicas y Polimedicado, a través de la realización de un ‘Programa de Intervención Poblacional para mejorar el uso de Fármacos en Pacientes Polimedicados’.